Brief summary of the legal proceeding.
The panel, held in Rome in April 2002 with the participation of more than 100 Italian directors of infectious diseases wards, followed a systematic approach to reviewing the evidence of any specific use of the genotypic assays to detect antiretroviral resistance. The single recommendations have been developed using a rating scheme based on consideration of the evidence and, when direct evidence was lacking, on expert opinion. Another emerging issue approached during this meeting is represented by the reproducibility of HIV-1 reverse transcriptase and protease sequencing in clinical settings. The degree of concordance of genotypic assays among 12 experienced laboratories is also reported.
Nicastri
Emanuele
E
National Institute for Infectious Diseases - IRCCS, Rome, Italy.
D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004279:DNA, Viral; D024882:Drug Resistance, Viral / Q000235:genetics*; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000175:diagnosis / Q000188:drug therapy*; D054303:HIV Reverse Transcriptase / Q000235:genetics; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D007558:Italy; D007603:Jurisprudence; D008297:Male; D008826:Microbial Sensitivity Tests; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy / Q000821:virology; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D018570:Risk Assessment; D012680:Sensitivity and Specificity
D019380:Anti-HIV Agents; D004279:DNA, Viral; D018894:Reverse Transcriptase Inhibitors; D054303:HIV Reverse Transcriptase